Novo Nordisk to Discontinue Long-Acting Insulin Levemir in the U.S. by End of 2024

Nov 10, 2023 13:38 CST Updated 13:38

Novo Nordisk

Insulin Developer and Manufacturer

Novo Nordisk announced on November 9, 2023,Will discontinue the long-acting insulin treatment drug Levemir (insulin detemir injection, trade name NovoPeace in China) in the United States by the end of next year (2024).

Novo Nordisk announced on its website that the discontinuation of drug production and sales is based onGlobal production restrictions, loss of prescriptions affecting patient access, and the availability of alternative options. Novo NordiskWill continue to supply Levemir FlexPen and Levemir vials to the wholesale market until stock runs out or until the discontinuation date, although supply is expected to be interrupted before then.

Novo Nordisk has provided a timetable for the cessation of production and sales in the United States:

Mid-January 2024:Levemir Injection Pen Supply Disruption
April 1, 2024:Levemir Injection Pen Discontinued
December 31, 2024:Including the Levemir vial, the entire brand has been completely discontinued.

There is currently no news on whether other regions around the world will be affected by the停产 of drugs in the United States.

At the beginning of 2023, influenced by pressure from the U.S. government and public opinion, among the three giants in the U.S. insulin sales market, Eli Lilly was the first to announce a price reduction for its insulin products. Subsequently, Novo Nordisk and Sanofi also agreed to lower the price of insulin.

"Soul-Cutting Price" Goes Global, US Insulin Triumvirate Pressured... Orz

March 14, 2023Novo Nordisk statedStarting January 1, 2024, the U.S. prices of several pre-filled insulin pens and vials will be reduced by more than 65%, includingLevemir。

Novo Nordisk announces production haltAfter Levemir，The other two insulin products under its umbrella — Fiasp (fast-acting aspart insulin) and NovoLog (aspart insulin) — will still participate in U.S. Medicare negotiations.。

The First Round of 10 Drugs for U.S. Medicare Negotiations Announced, All Blockbusters! Sold Over $700 Billion Last Year……

Source: Novo to Discontinue Long-Acting Insulin Injection Levemir by the End of 2024 | BioSpace

A Global Bestseller, but May Fall Short of Expectations in China? Has the DS-8201 Containment Strategy Succeeded?

Weight Loss Exceeds 20%, $1060/Month! Eli Lilly's Tirzepatide Approved for Obesity Indication

Finally, after 558 days, the products of Hutchmed and Junshi have been approved for marketing by the FDA.

ClickIn ViewCooperative New Drug R&D Wave